Patients# | TDI | CCQ | CAT | FEV1 | |
Age years | |||||
<65 | 2077 | 993 (47.8) | 610 (29.4) | 817 (39.3) | 874 (42.1) |
≥65 | 2247 | 1015 (45.2) | 563 (25.1) | 768 (34.2) | 806 (35.9) |
Sex | |||||
Female | 1416 | 648 (45.8) | 416 (29.4) | 531 (37.5) | 505 (35.7) |
Male | 2908 | 1360 (46.8) | 757 (26.0) | 1054 (36.2) | 1175 (40.4) |
Smoking status | |||||
Current smoker | 2292 | 1106 (48.3) | 664 (29.0) | 878 (38.3) | 908 (39.6) |
Ex-smoker | 2028 | 901 (44.4) | 507 (25.0) | 705 (34.8) | 772 (38.1) |
Never-smoker | 4 | 1 (25.0) | 2 (50.0) | 2 (50.0) | 0 (0.0) |
Exacerbations in previous 12 months | |||||
0 | 3441 | 1602 (46.6) | 941 (27.3) | 1277 (37.1) | 1359 (39.5) |
≥1 | 883 | 406 (46.0) | 232 (26.3) | 308 (34.9) | 321 (36.4) |
Baseline FEV1 % pred | |||||
<60% | 1367 | 617 (45.1) | 357 (26.1) | 476 (34.8) | 555 (40.6) |
≥60% | 2948 | 1389 (47.1) | 816 (27.7) | 1108 (37.6) | 1124 (38.1) |
Bronchodilator reversibility | |||||
≤12% | 3251 | 1521 (46.8) | 866 (26.6) | 1197 (36.8) | 1060 (32.6) |
>12% | 1067 | 486 (45.5) | 307 (28.8) | 387 (36.3) | 619 (58.0) |
Data are presented as n or n (%). TDI: Transition Dyspnoea Index; CCQ: Clinical COPD Questionnaire; CAT: COPD Assessment Test. #: total number of patients; some of the responders showed response to more than one PRO and/or FEV1.